Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10520834 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL21614019 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL2558769 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL2558767 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL10521489 | 0.99 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL10521485 | 0.99 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL5416277 | 0.84 | DPP4 (0.54) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL5416280 | 0.84 | DPP4 (0.54) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL16314357 | 0.84 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL12383609 | 0.82 | HSD17B10 (0.55) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039280-A1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | Seagen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190336614-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-9242013-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2558127-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | Seattle Genetics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | DPP4 552/4885DPP8 1241/4885DPP9 264/4885 |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | QDPR, SBDS, DNPEP | DPP4 552/4885DPP8 1241/4885DPP9 264/4885 |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | DPP4 552/4885DPP8 1241/4885DPP9 264/4885 |
| US-20190336614-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | DPP4 552/4885DPP8 1241/4885DPP9 264/4885 |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | DPP4 552/4885DPP8 1241/4885DPP9 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.